AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.650
-0.060 (-2.21%)
Aug 28, 2026, 4:00 PM EDT - Market closed
AC Immune Revenue
AC Immune had revenue of 15.11M CHF in the quarter ending June 30, 2026, with 1,057.20% growth. This brings the company's revenue in the last twelve months to 17.51M, down -39.45% year-over-year. In the year 2025, AC Immune had annual revenue of 3.57M, down -86.92%.
Revenue (ttm)
17.51M CHF
Revenue Growth
-39.45%
P/S Ratio
12.16
Revenue / Employee
143,516 CHF
Employees
122
Market Cap
263.48M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.57M | -23.74M | -86.92% |
| Dec 31, 2024 | 27.31M | 12.51M | 84.51% |
| Dec 31, 2023 | 14.80M | 10.87M | 276.14% |
| Dec 31, 2022 | 3.94M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 15.43M | -95.03M | -86.03% |
| Dec 31, 2019 | 110.46M | 103.54M | 1,498.03% |
| Dec 31, 2018 | 6.91M | -13.34M | -65.88% |
| Dec 31, 2017 | 20.26M | -2.96M | -12.75% |
| Dec 31, 2016 | 23.21M | -15.88M | -40.61% |
| Dec 31, 2015 | 39.09M | 8.82M | 29.14% |
| Dec 31, 2014 | 30.27M | 21.63M | 250.46% |
| Dec 31, 2013 | 8.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Niagen Bioscience | 129.08M |
| Cellectis | 63.82M |
| Alector | 13.86M |
| Surrozen | 11.51M |
| Pyxis Oncology | 11.04M |
| Whitehawk Therapeutics | 7.15M |
| Camp4 Therapeutics | 4.22M |
ACIU News
- 10 days ago - AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 - GlobeNewsWire
- 19 days ago - AC Immune receives fast track designation, clearance for ACI-7104 IND - TheFly
- 25 days ago - AC Immune First Half 2026 Financial and Corporate Update - GlobeNewsWire
- 7 weeks ago - AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - GlobeNewsWire
- 2 months ago - AC Immune announces interim data from first three cohorts of ABATE trial - TheFly
- 2 months ago - AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease - GlobeNewsWire
- 2 months ago - AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease - GlobeNewsWire
- 3 months ago - AC Immune Slides: Investor presentation - Filings